Identification of Human Butyrylcholinesterase Organophosphate-Resistant Variants through a Novel Mammalian Enzyme Functional Screen

Abstract

Human butyrylcholinesterase (hBChE) is currently being developed as a detoxication enzyme for the catalytic hydrolysis or stoichiometric binding of organophosphates (OPs). Previously, rationally designed hBChE mutants (G117H and E197Q) were reported in the literature and showed the feasibility of engineering OP hydrolytic functional activity into hBChE. However, the OP hydrolysis rate for G117H is too low for clinical utility. Additional OP-resistant hBChE variants with greater hydrolysis rates are needed as OP nerve-agent countermeasures for therapeutic utility. As described herein, a directed molecular evolution process was used to identify amino acid residues that contribute to OP-resistant functional activity of hBChE variants. In this article, we describe the development and validation of a novel method to identify hBChE variants with OP-resistant functional activity (decreased rate of OP inhibition). The method reported herein used an adenoviral protein expression system combined with a functional screening protocol of OP nerve-agent model compounds that have been shown to have functional properties similar to authentic OP nerveagent compounds. The hBChE screening method was robust for transfection efficiency, library diversity, and reproducibility of positive signals. The screening approach not only identified the previously reported hBChE G117H variant, but also identified a series of additional hBChE variants, including hBChE G117N, G117R, E197C, and L125V, that exhibited OP-resistant functional activities not reported previously. The mammalian functional screening approach can serve as a cornerstone for further optimization and screening for OPresistant hBChEs for potential therapeutic applications.

Beyond the outer limits of nature by directed evolution

“…However, its reaction with nerve agents requires some improvement as it is inactivated when it complexes with the substrate. Rational design yielded variants with slightly increased resistance to OPs but with reduced catalytic efficiency (Zhang et al, 2012a). However, evolution of this same enzyme with nerve agent analogues identified three variants with increased resistance to these compounds while retaining high catalytic efficiency.…”

Organophosphate Exposure

“…Using a novel adenovirus-mediated mammalian BChE functional screen approach, our group identified several variants including G117R, G117N, E197C, and L125V that showed promising enzyme kinetics in OP resistance [94]. Although the physiological function of BChE is still not clear, it has been shown that exogenously administered BChE provides effective protection against OP exposure.…”

Untitled

“…The inhibitory activity was measured by a spectrophotometric method 15 . The reaction mixture contained 190µl Trizma buffer (100mM) (pH 8.0), 20µl of the sample and 40µl of butyrylcholinesterase solution (0.035U/ml) were mixed and incubated for 30min (4 °C).…”